CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. Key Findings

3.2.1. Top investment pockets
3.2.2. Top player positioning, 2016

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Increase in number of surgical procedures
3.3.1.2. Rise in prevalence of chronic diseases
3.3.1.3. Rise in risk of malnutrition

3.3.2. Restraints

3.3.2.1. Risk of allergic reaction and infection
3.3.2.2. Preference for enteral route of administration

3.3.3. Opportunities

3.3.3.1. Upsurge in demand for palliative care

CHAPTER 4: AFRICA LARGE VOLUME PARENTERALS MARKET, BY TREATMENT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Fluid balance injections

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast

4.3. Therapeutic Injections

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast

4.4. Nutritious injections

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast

CHAPTER 5: AFRICA LARGE VOLUME PARENTERALS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Intravenous

5.2.1. Market size and forecast

5.3. Intramuscular

5.3.1. Market size and forecast

5.4. Subcutaneous

5.4.1. Market size and forecast

5.5. Other routes

5.5.1. Market size and forecast

CHAPTER 6: AFRICA LARGE VOLUME PARENTERALS MARKET, BY CAPACITY

6.1. Overview

6.1.1. Market size and forecast

6.2. 100 ml

6.2.1. Market size and forecast

6.3. 250 ml

6.3.1. Market size and forecast

6.4. 500 ml

6.4.1. Market size and forecast

6.5. 1000 ml

6.5.1. Market size and forecast

6.6. 2000 ml

6.6.1. Market size and forecast

CHAPTER 7: AFRICA LARGE VOLUME PARENTERALS MARKET, BY COUNTRY

7.1. Overview

7.1.1. Market size and forecast

7.2. South Africa

7.2.1. Market size and forecast

7.3. Zimbabwe

7.3.1. Market size and forecast

7.4. Namibia

7.4.1. Market size and forecast

7.5. Rest of Africa

7.5.1. Market size and forecast

CHAPTER 8: COMPANY PROFILE

8.1. Parenteral Drugs (India) Ltd.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Adcock Ingram Holdings Ltd.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. Pharmacure PLC

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Product portfolio

8.4. Datlabs Private Limited

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. Erongo Med

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio

8.6. Addis Pharmaceutical Factory PLC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments

8.7. Abacus Parenteral Drugs Limited

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product portfolio